As of Sep 22
| +0.18 / +0.54%|
The 12 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 23.50, with a high estimate of 36.00 and a low estimate of 16.00. The median estimate represents a -30.45% decrease from the last price of 33.79.
The current consensus among 15 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.